Clinical Development / Neurology
Neurological Disease
Liferna is advancing investigational therapies for peripheral neuropathies and other neurological diseases with significant unmet medical needs.
LFR-1501
Neuronal Regeneration-Promoting Cell Therapy
An investigational, allogeneic cell-therapy program being developed for peripheral neuropathies.
LFR-1501 Clinical Studies
Select an indication to view completed and planned studies.
Charcot-Marie-Tooth Disease Type 1
A rare inherited peripheral neuropathy affecting motor and sensory nerves.
Phase 1 study
Conducted in South Korea
Phase 2 study
Further clinical evaluation
Diabetic Neuropathy
A common peripheral neuropathy associated with diabetes.
Phase 1 study
Initial clinical evaluation
Additional studies can be added as the program advances.
Additional neurology programs and clinical studies can be incorporated as the portfolio expands.
LFR-1501 is investigational and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
Planned studies are subject to regulatory review and may change.
